About Organogenesis Holdings Inc.
https://organogenesis.comOrganogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
CEO
Gary S. Gillheeney
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 75
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:12.13M
Value:$46.95M
MORGAN STANLEY
Shares:11.8M
Value:$45.65M
FIRST LIGHT ASSET MANAGEMENT, LLC
Shares:7.5M
Value:$29.02M
Summary
Showing Top 3 of 138
About Organogenesis Holdings Inc.
https://organogenesis.comOrganogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $150.86M ▲ | $93.89M ▲ | $21.57M ▲ | 14.3% ▲ | $0.11 ▲ | $27.26M ▲ |
| Q2-2025 | $100.78M ▲ | $85.72M ▼ | $-9.39M ▲ | -9.32% ▲ | $-0.1 ▲ | $-6.25M ▲ |
| Q1-2025 | $86.69M ▼ | $89.72M ▲ | $-18.84M ▼ | -21.74% ▼ | $-0.17 ▼ | $-15.89M ▼ |
| Q4-2024 | $126.66M ▲ | $85.39M ▲ | $7.67M ▼ | 6.06% ▼ | $0.06 ▼ | $14.64M ▲ |
| Q3-2024 | $115.18M | $82.14M | $12.33M | 10.71% | $0.09 | $10.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $64.37M ▼ | $509.83M ▲ | $123.85M ▲ | $385.98M ▲ |
| Q2-2025 | $73.08M ▼ | $461.13M ▼ | $99.91M ▲ | $361.22M ▼ |
| Q1-2025 | $109.97M ▼ | $467.39M ▼ | $99.33M ▼ | $368.07M ▼ |
| Q4-2024 | $135.57M ▲ | $497.89M ▲ | $112.57M ▼ | $385.32M ▲ |
| Q3-2024 | $94.34M | $446.3M | $167.75M | $278.55M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $21.57M ▲ | $3.08M ▲ | $-2.23M ▲ | $-10.21M ▼ | $-9.36M ▲ | $844K ▲ |
| Q2-2025 | $-9.39M ▲ | $-32.87M ▼ | $-3.64M ▼ | $-288K ▲ | $-36.8M ▼ | $-36.51M ▼ |
| Q1-2025 | $-18.84M ▼ | $-19.93M ▼ | $-3.63M ▼ | $-2.06M ▼ | $-25.62M ▼ | $-23.56M ▼ |
| Q4-2024 | $7.67M ▼ | $10.94M ▲ | $-3.36M ▼ | $33.65M ▲ | $41.23M ▲ | $7.58M ▲ |
| Q3-2024 | $12.33M | $8.7M | $-2.57M | $-1.68M | $4.45M | $6.13M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Advanced Wound care | $240.00M ▲ | $0 ▼ | $0 ▲ | $80.00M ▲ |
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $0 ▲ | $150.00M ▲ | $100.00M ▼ | $0 ▼ |
 Surgical and Sports Medicine | $20.00M ▲ | $0 ▼ | $0 ▲ | $10.00M ▲ |
CEO
Gary S. Gillheeney
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 75
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:12.13M
Value:$46.95M
MORGAN STANLEY
Shares:11.8M
Value:$45.65M
FIRST LIGHT ASSET MANAGEMENT, LLC
Shares:7.5M
Value:$29.02M
Summary
Showing Top 3 of 138